C4 Therapeutics Inc (CCCC NASDAQ) stock market data APIs
$2.04
0.25(12.3%)
as of December 17, 2025
Try our APIs with
free plan!
C4 Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
2.04
Open
2.2899
High
2.2956
Low
2.0291
52 wk Range
1.085-4.26
Market Cap
219 M
Shares Outstanding
96 914 K
Revenue
30 108 K
EPS
-0.2954
Beta
2.886
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with C4 Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get C4 Therapeutics Inc data using free add-ons & libraries
Get C4 Therapeutics Inc Fundamental Data
C4 Therapeutics Inc Fundamental data includes:
- Net Revenue: 30 108 K
- EBITDA: -117 042 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.4057
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
C4 Therapeutics Inc News
New
How Recent Developments Are Rewriting the Story for Biogen
Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around po...
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics files $400M mixed shelf offering
[Shares Certificate] Bluberries * C4 Therapeutics (CCCC [https://seekingalpha.com/symbol/CCCC]) has filed a shelf registration to offer up to $400M in securities. * The offering [https://seekinga...
![[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)](/build/assets/fallback2-B-N5xr-q.jpg)
[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size &...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
